A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment.
Difede J, McAleavey AA, Emrich M, Jick A, Ovalles A, Wyka K, Spielman L, Olden M, Peskin M, Becket-Davenport C, Rubenstein A, Brownstein MJ, Damiano E, Itzkowitz D, Lu SF, Needell NJ, Kocsis JH, Gordon-Elliott JS, Simon NG.
Difede J, et al. Among authors: emrich m.
Contemp Clin Trials Commun. 2023 Mar 17;33:101116. doi: 10.1016/j.conctc.2023.101116. eCollection 2023 Jun.
Contemp Clin Trials Commun. 2023.
PMID: 37008794
Free PMC article.